Does receipt of chemoimmunotherapy for LS-SCLC impact your recommendation for PCI?

Historic data showed that the addition of PCI for patients with limited-stage small cell lung cancer showing response after chemoradiotherapy improves overall survival and decreases brain failure rates by about 50%. Recently, the addition of consolidation immunotherapy after concurrent chemoradiothe...

As someone who dislikes whole brain and would very much like to see it disappear in my career, I would agree that the standard of care currently for limited SCLC would be to offer PCI, even in the setting of the ADRIATIC trial where one could potentially speculate that there may be some intracranial...

PCI continues to be studied despite advocacy for omission in most cases, waiting for CNS relapse. There has been advocacy for hippocampal sparing or the use of drugs to prevent neurocognitive events attributed to PCI. In my view, there are clear cases to *not* use: poor ps, over 70, and those at low...

Neurocognitive toxicities associated with PCI are often misattributed and, unfortunately, exaggerated by SRS enthusiasts. They are generally "treatment-related" and confounded by chemotherapy (or ethanol, as Dr. @Dr. First Last eludes). So, it's unclear whether PCI is a primary culprit for cognitive...

I agree that the standard of care remains PCI until proven otherwise in prospective trials, while active surveillance with MRI can be a reasonable alternative to present to patients as well. Having treated many patients with PCI myself, I also agree with Drs. @Dr. First Last and @Dr. First Last that...